AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00818246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LumiPhase-R™, OPUSMED Inc. Montreal, Canada
Description: 660 nm wavelength delivered in a sequential pulsing mode
Study NCT04762836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: Antibiotic medication that augments the function of NMDA-receptors
Study NCT04762836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditioning
Description: During nocebo acquisition trials, the conditioned stimulus (i.e., activation of a sham electrode that can increase pain sensitivity, is paired to unconditioned high-pain stimuli (nocebo trials). During control trials of the acquisition phase, moderate-pain stimuli are paired to no sham electrode activation.
Study NCT04762836 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Conditioning
Description: During nocebo acquisition trials, the conditioned stimulus (i.e., activation of a sham electrode that can increase pain sensitivity, is paired to unconditioned high-pain stimuli (nocebo trials). During control trials of the acquisition phase, moderate-pain stimuli are paired to no sham electrode activation.
Study NCT04762836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extinction
Description: During nocebo extinction, moderate pain stimulations are administered both after the administration of the conditioned stimulus (i.e., activation of the sham electrode) and the control stimulus (no activation of the sham electrode), in order to evoke nocebo responses to the sham hyperalgesic procedure.
Study NCT04762836 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Extinction
Description: During nocebo extinction, moderate pain stimulations are administered both after the administration of the conditioned stimulus (i.e., activation of the sham electrode) and the control stimulus (no activation of the sham electrode), in order to evoke nocebo responses to the sham hyperalgesic procedure.
Study NCT04762836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: In both arms of the study, BOLD response data will be collected with fMRI during the acquisition and extinction of nocebo effects on pain.
Study NCT04762836 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fMRI
Description: In both arms of the study, BOLD response data will be collected with fMRI during the acquisition and extinction of nocebo effects on pain.
Study NCT04762836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control in oral form
Study NCT06235918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab: 200mg,administered via Intravenous (IV) injection, day 1 of each 21-day cycle, neoadjuvant therapy : 2 cycles
Study NCT06235918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 260mg/m\^2, IV, day 1 of each 21-day cycle, neoadjuvant therapy : 2 cycles
Study NCT06235918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 mg/mL/min by IV infusion once every 3 weeks,day 1 of each 21-day cycle,neoadjuvant therapy : 2 cycles
Study NCT05797363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous midwife support
Description: The individuals included in the experimental group will be provided with consultancy services on many issues from the pre-pregnancy period to the postpartum period.
Study NCT04767672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Non digestible carbohydrates
Description: the subjects will consume 2 bags of 10 grams per day of the product: 1 bag in the morning and 1 bag at lunch or in the evening, at the beginning of the meal, diluted in a large glass of beverage, during 12 weeks.
Study NCT06185894 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterovesical tourniquet before uterine devascularization steps
Description: Insertion of a Foley catheter tourniquet through broad ligament apertures \& tightening it immediately before hysterotomy in cases of conservative management of placenta accreta spectrum
Study NCT06185894 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional conservative surgery
Description: Conventional conservative surgery
Study NCT06195293 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen Polypeptide Vaccine
Description: Deliver neoantigen polypeptide vaccine into patients for anti-ancer therapy.
Study NCT04711499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fatigue
Description: The intervention will be assessing the participant in a fatigued state compared to a non fatigued state
Study NCT04711499 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fatigue
Description: The intervention will be assessing the participant in a fatigued state compared to a non fatigued state
Study NCT06422429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Traditional deep-fried Youtiao
Description: 45g 4 times a week for 4 months
Study NCT06422429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI Youtiao
Description: 45g 4 times a week for 4 months
Study NCT05400187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body composition assessment and smart-phone based counselling
Description: As for the body composition assessment, body fat and muscle thickness, body fat percentage and distribution will be measured and a brief face-to-face counseling soon after the measurement will be implemented to the participants. Body assessment were measured by the InBody 270 (Biospace, Seoul, Korea) device, which provides a convenient way of accurate body fat measurement comparable with those obtained using air displacement plethysmography (ADP) (about 90% precision).~As for the Whatsapp-based counselling and communication session, qualitative dietary counselling will be offered every two weeks through the Whatsapp. One session contains 15 minutes, including the topics like making a balanced diet (55 % glucose, 30 % lipids and 15 % proteins), diversifying food intake, dietary advices and recommendations in healthy eating behaviors (e.g., eat slowly, eat at a regular time, avoid to skip a meal, drink at least 1.5 L of water each day).
Study NCT04705337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: administration of levosimendan as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)
Study NCT04705337 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administration of glucose as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)
Study NCT06495216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation by a Balloon Catheter with the TRUPULSE Generator
Description: Pulsed field ablation balloon catheter and TRUPULSE generator will be used for PV ablation.
Study NCT06342648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sterile Water Injection
Description: Injection of intracutaneous sterile water
Study NCT06342648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium injection
Description: Injection of intramuscular diclofenac sodium
Study NCT06366334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: See arm description
Study NCT06366334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: See arm description
Study NCT05982834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin combined with fruquintinib and Tislelizumab
Description: Disitamab Vedotin 2.5mg/m2 ivgtt d1,15, fruquintinib 4mg qd po d1-21 and Tislelizumab 300mg ivgtt,q4w
Study NCT05082402 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Swept Source Optical Coherence Tomography Angiography
Description: The PLEX Elite 9000 is an FDA cleared research device for use in ocular imaging obtained by Northwestern University by way of a purchase agreement with the manufacturer, Carl Zeiss Meditec, Inc. It is currently unavailable outside of participation in the ARI Network, a cloudbased storage and image processing platform using deidentified information shared between academic institutions. The ARI Network is managed by a group of physicians and scientists from around the world that are working to better understand eye diseases.
Study NCT04942119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Description: 1. Correction of magnesium and/or potassium deficit and the underlying disease.~2. Education reinforcing optimal diet and exercise, in addition to, post-nutrition assessment , diabetes self-care activities and adherence will be given at each follow up visit by a specialized dietitian.~3. Comprehensive medication therapy management by clinical pharmacist, and medication adherence will be measured by adherence questionnaire as well as fixed medication possession ratio (FMPR).
Study NCT05178693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: Cedazuridine 100mg + 35mg decitabine
Study NCT05178693 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Lutathera
Description: Peptide receptor radionuclide therapy (PRRT)
Study NCT01600001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KWA-0711
Study NCT01600001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05306548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical carpal tunnel release
Description: Open surgical division of the flexor retinaculum of the palm/wrist to release pressure on the median nerve
Study NCT05306548 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical carpal tunnel release
Description: Open surgical division of the flexor retinaculum of the palm/wrist to release pressure on the median nerve
Study NCT05306548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection, Triamcinolone Hexacetonide, Per 5 Mg
Description: Ultrasound-guided injection of 20 mg of triamcinolone hexacetonide (or -acetonide) into the carpal tunnel space close to the median nerve
Study NCT04698655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information on treatment options
Description: Asked to read two A4 pages of information on treatment options (osteoarthritis treatment options)
Study NCT04740333 — intervention group
Intervention type: OTHER
Intervention: No intervention- observational study
Description: No intervention- observational study
Study NCT05020613 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Procedure: Early removal group
Description: Participants assigned this arm will have their urethral catheters removed at 2 days after low anterior resection of the rectum
Study NCT05020613 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Procedure: Late removal group
Description: Participants assigned this arm will have their urethral catheters removed after 48.th hours after Low anterior resection of the rectum
Study NCT06139536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT4706 Injection
Description: Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.
Study NCT06139536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1308 Injection
Description: Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.
Study NCT05806112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resiliency Training
Description: The Stress Management and Resiliency Training: Relaxation Response Resiliency Program (SMART-3RP) has been shown to be effective in improving resilience and reducing distress among individuals across different populations and settings. The SMART-3RP enhances resilience by 1) teaching tools to elicit the relaxation response (RR) to offset negative effects of chronic stress; 2) improving stress management and awareness; and 3) promoting growth enhancement and agency to effect positive change. It blends stress coping principles from mind-body, cognitive-behavioral, and positive psychology theory to teach skills to advance each of these resiliency processes. The training will be delivered in six 50-minute virtual group sessions with 2 optional booster sessions available for those who desire additional sessions to further consolidate the core resiliency skills.
Study NCT05806112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task Sharing
Description: Task Sharing is a process involving health care workers in partnership with others in which workers retain many of their primary tasks, but some tasks are completed collaboratively or by other workers or volunteers in a shared effort. Study coaches will work with the group home directors and RCWs to identify shared tasks that may be conducted by peers or resident volunteers by task co-assignment with supervision and support. Task co-assignments will be discussed in routine house meetings occurring on a weekly basis and incorporated into a jointly developed house plan. The house plan will engage staff and residents to identify shared activities to reduce the burden on RCWs through task co-assignment and team-based efforts aimed at tasks that create unnecessary burden and stress for RCWs, yet do not require RCWs to complete them.
Study NCT05806112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workplace Improvement Learning Collaborative
Description: The Workplace Improvement Learning Collaborative (WILC) consists of identifying major sources of RCW burnout across the system and then instituting an organizational (agency-wide) measure to address the identified sources of burnout by restructuring tasks (e.g., reducing administrative burdens, increasing workflow efficiencies) through a virtual earning collaborative with group home leaders. Learning collaboratives commonly use a structured framework within which teams learn about research and best practices, apply quality-improvement methods, and exchange their experiences in making improvements with the widespread use of such collaboratives. Program Directors will participate in a learning collaborative facilitated by trained and certified study coaches to identify and collaboratively develop and implement effective strategies to address root causes of RCW burnout across group homes and program directors assigned to the WILC intervention.
Study NCT04767672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the subjects will consume 2 bags of 10 grams per day of the product: 1 bag in the morning and 1 bag at lunch or in the evening, at the beginning of the meal, diluted in a large glass of beverage, during 12 weeks.
Study NCT04777604 — intervention group
Intervention type: OTHER
Intervention: Organoid
Description: The investigators create organoid from the pancreatic cancer tissue obtained via EUS-FNA and EUS-FNB within the pancreatic cancer diagnostic process. And also the investigators create organoid from the pancreatic cancer tissue obtained after surgery as part of the pancreatic cancer treatment process. Check for the reactivity to anti-cancer drugs through cell viability assay after treating with various anti-cancer drugs, such as anti-cancer drugs used as neoadjuvant chemotherapy for pancreatic cancer to the organoid. Also, perform genomic analysis on each organoid, and then check if there are any unique genomic mutations for each organoid. By recognizing the relationship between the unique genomic mutations and reactivity to the anti-cancer drug within patients with resectable pancreatic cancer after neoadjuvant chemotherapy, the investigators aim to strategize appropriate neoadjuvant chemotherapy before surgery, thus developing a platform to predict the outcomes of each patient.
Study NCT06364384 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PD-1 and CRT
Description: Chemotherapy (/3w): 1)DDP 75 mg/m2, d1, intravenous infusion; 2)5-FU 1000 mg/m2, d1-4, continuous pumping intravenously; Immunotherapy (/3w): PD-1 monoclonal antibody(sintilimab) 200mg, d1, intravenous infusion; Radiotherapy (at 3rd week after first time of chemotherapy):Daily single dose of 2Gy, with a total dose of 50-54GY.
Study NCT04656288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764198 - Formula A
Description: BI 764198
Study NCT04656288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764198 - Formula B
Description: BI 764198
Study NCT04656288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764198 - Formula C
Description: BI 764198
Study NCT04656288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764198 - Formula D
Description: BI 764198
Study NCT06219668 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Omentopexy group
Description: Omentopexy and Clips on staple line during LSG
Study NCT05767788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Movement with Mobilization (MWM)
Description: Painful active functional knee movement is identified. The most comfortable passive medial, lateral, medial rotatory, lateral rotatory, postero-anterior, and antero-posterior glide, is applied to the knee of the patient.~Three sets of 10 repetitions are applied. Corresponding home MWM exercise is taught. The treatment is conducted for 12 sessions over 6 weeks.
Study NCT05767788 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Movement with Mobilization (Sham MWM)
Description: Painful active functional knee movement is identified. The most comfortable passive medial, lateral, medial rotatory, lateral rotatory, postero-anterior, and antero-posterior light-touch glide, is applied to the knee of the patient.~Three sets of 10 repetitions are applied. Corresponding home MWM exercise is taught. The treatment is conducted for 12 sessions over 6 weeks.
Study NCT03752203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluorescein
Description: Patients enrolled in this study will receive 3 mg/kg sodium fluorescein following induction of anesthesia by administration into a peripheral venous line over 10 seconds
Study NCT03752203 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microscopic Resection
Description: Resection will proceed with the use of a surgical microscope equipped with excitation and barrier filters for monitoring with sufficient fluorescent enhancement and contrast.
Study NCT05568563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethyl chloride
Description: Ethyl chloride is an agent that is widely used in dental practice as the standard modality for pulp vitality tests .
Study NCT05568563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Honey
Description: Honey is a natural dietary product
Study NCT05618756 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute oral CBD supplementation
Description: 1 ml hemp oil containing 300 mg CBD, within gelatin capsules, ingested orally.
Study NCT05618756 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Acute oral placebo supplementation
Description: 1 ml hemp oil containing no CBD, within gelatin capsules, ingested orally.
Study NCT06555341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Six Thinking Hats Group
Description: 2. Subcutaneous insulin administration was explained with the traditional training model.~3. The Six Thinking Hats technique and how it is used was then explained in detail to the students. Any points that were not fully understood were explained again so that the technique was thoroughly reinforced.~4. The researchers had made hats from different coloured card. All the students wore all the hats in turn and were asked the questions related to that colour hat as stated above (semi-structured questionnaire 1-6).~5. The responses given by the students to the questions were audio-recorded. Each interview lasted 30 mins.
Study NCT06555341 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Other: Video Group
Description: 2. Subcutaneous insulin administration was explained with the traditional training model.~3. Then by scanning the QR code from the nursing practice skills textbook(Aylaz \&amp; Yakıncı, 2024), the researchers provided the link for the students to watch the insulin application video.~4. Without mentioning hat colours or the Six Thinking Hats method to this group, the questions on the semi-structured questionnaire were asked, and the interviews, each lasting 30 mins, were audio-recorded.~5. After completing the video training, the mid-test data were collected by applying the Subcutaneous Insulin Application Skill Level Observation Form during administration of insulin to a dummy.
Study NCT05075720 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Meat with added nitrate
Description: The intervention comprises 50 g salami and 35 g ham on white bread sandwich at breakfast and lunch.~This intervention will allow us to determine both endogenous formation of N-nitrosamines as well as N-nitrosamines present in the commercially prepared meat.
Study NCT05075720 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meat with added nitrate
Description: The intervention comprises 50 g salami and 35 g ham on white bread sandwich at breakfast and lunch.~This intervention will allow us to determine both endogenous formation of N-nitrosamines as well as N-nitrosamines present in the commercially prepared meat.
Study NCT05075720 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Meat without added nitrate
Description: The intervention comprises 65 g Pork mince on white bread sandwich at breakfast and lunch. Nitrate is not an allowed additive in pork mince.~This intervention will allow us to determine if there is endogenous formation of N-nitrosamines as well as N-nitrosamines present in the prepared meat due to the natural content of nitrate in meat.